Zbigniew Zaslona

Zbigniew Zaslona

Auto-generated profile, based on publicly available information

Zbigniew Zaslona

Molecure S.A., Warsaw, Poland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2018 in Nature
Verified
Journal Article
Closed access
PDF file
EMEvanna L. Mills
Evanna L. Mills
DRDylan G. Ryan
Dylan G. Ryan
HPHiran A. Prag
Hiran A. Prag
DDDina Dikovskaya
Dina Dikovskaya
DMDeepthi Menon
Deepthi Menon
LOLuke A. O’neill
Luke A. O’neill

20 August 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JEJames O. Early
James O. Early
DMDeepthi Menon
Deepthi Menon
CWCathy A. Wyse
Cathy A. Wyse
MCMariana P. Cervantes-Silva
Mariana P. Cervantes-Silva
ZZZbigniew Zaslona
Zbigniew Zaslona
ACAnnie M. Curtis
Annie M. Curtis
Significance: The molecular clock provides an anticipatory mechanism, allowing organisms to prepare and respond to daily changes in the external environment. The response of the innate immune system to pathogenic threats is dependent on time of day; however, the molecular mechanisms underlying this have yet to be fully uncovered. We observe that the core molecular clock component, BMAL1, is crucial in promoting an antioxidant response in myeloid cells. Deletion of Bmal1 in macrophages disrupts NRF2 activity, facilitating accumulation of reactive oxygen species and the proinflammatory cytokine, IL-1β. Thus the molecular clock directly controls NRF2 transcriptional activity and antioxidant capacity to regulate IL-1β in myeloid cells.

15 October 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ZZZbigniew Zasłona
Zbigniew Zasłona
SPSally Przybranowski
Sally Przybranowski
CWCarol Wilke
Carol Wilke
NRNico van Rooijen
Nico van Rooijen
STSeagal Teitz-Tennenbaum
Seagal Teitz-Tennenbaum
MPMarc Peters-Golden
Marc Peters-Golden
The role and origin of alveolar macrophages (AMs) in asthma are incompletely defined. We sought to clarify these issues in the context of acute allergic lung inflammation using house dust mite and OVA murine models. Use of liposomal clodronate to deplete resident AMs (rAMs) resulted in increased levels of inflammatory cytokines and eosinophil numbers in lavage fluid and augmented the histopathologic evidence of lung inflammation, suggesting a suppressive role for rAMs. Lung digests of asthmatic mice revealed an increased percentage of Ly6Chigh/CD11bpos inflammatory monocytes. Clodronate depletion of circulating monocytes, by contrast, resulted in an attenuation of allergic inflammation. A CD45.1/CD45.2 chimera model demonstrated that recruitment at least partially contributes to the AM pool in irradiated nonasthmatic mice, but its contribution was no greater in asthma. Ki-67 staining of AMs supported a role for local proliferation, which was increased in asthma. Our data demonstrate that rAMs dampen, whereas circulating monocytes promote, early events in allergic lung inflammation. Moreover, maintenance of the AM pool in the early stages of asthmatic inflammation depends on local proliferation, but not recruitment.

6 April 2015 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
EBEmilie Bourdonnay
Emilie Bourdonnay
ZZZbigniew Zasłona
Zbigniew Zasłona
LPLoka Raghu Kumar Penke
Loka Raghu Kumar Penke
JSJennifer Speth
Jennifer Speth
DSDaniel J. Schneider
Daniel J. Schneider
MPMarc Peters-Golden
Marc Peters-Golden
JAK-STAT signaling mediates the actions of numerous cytokines and growth factors, and its endogenous brake is the family of SOCS proteins. Consistent with their intracellular roles, SOCS proteins have never been identified in the extracellular space. Here we report that alveolar macrophages can secrete SOCS1 and -3 in exosomes and microparticles, respectively, for uptake by alveolar epithelial cells and subsequent inhibition of STAT activation. Secretion is tunable and occurs both in vitro and in vivo. SOCS secretion into lung lining fluid was diminished by cigarette smoking in humans and mice. Secretion and transcellular delivery of vesicular SOCS proteins thus represent a new model for the control of inflammatory signaling, which is subject to dysregulation during states of inflammation.

1 April 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RCRichard G. Carroll
Richard G. Carroll
ZZZbigniew Zasłona
Zbigniew Zasłona
SGSilvia Galván-Peña
Silvia Galván-Peña
EKEmma L. Koppe
Emma L. Koppe
DSDaniel C. Sévin
Daniel C. Sévin
Luke O'NeillLuke O'Neill
Luke O'Neill
Different immune activation states require distinct metabolic features and activities in immune cells. For instance, inhibition of fatty acid synthase (FASN), which catalyzes the synthesis of long-chain fatty acids, prevents the proinflammatory response in macrophages; however, the precise role of this enzyme in this response remains poorly defined. Consistent with previous studies, we found here that FASN is essential for lipopolysaccharide-induced, Toll-like receptor (TLR)-mediated macrophage activation. Interestingly, only agents that block FASN upstream of acetoacetyl-CoA synthesis, including the well-characterized FASN inhibitor C75, inhibited TLR4 signaling, while those acting downstream had no effect. We found that acetoacetyl-CoA could overcome C75's inhibitory effect, whereas other FASN metabolites, including palmitate, did not prevent C75-mediated inhibition. This suggested an unexpected role for acetoacetyl-CoA in inflammation that is independent of its role in palmitate synthesis. Our evidence further suggested that acetoacetyl-CoA arising from FASN activity promotes cholesterol production, indicating a surprising link between fatty acid synthesis and cholesterol synthesis. We further demonstrate that this process is required for TLR4 to enter lipid rafts and facilitate TLR4 signaling. In conclusion, we have uncovered an unexpected link between FASN and cholesterol synthesis that appears to be required for TLR signal transduction and proinflammatory macrophage activation.

13 October 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
EPEva M. Palsson-McDermott
Eva M. Palsson-McDermott
LDLydia Dyck
Lydia Dyck
ZZZbigniew Zasłona
Zbigniew Zasłona
DMDeepthi Menon
Deepthi Menon
AMAnne F. McGettrick
Anne F. McGettrick
LOLuke A. O’nEill
Luke A. O’nEill
Blocking interaction of the immune checkpoint receptor PD-1 with its ligand PD-L1 is associated with good clinical outcomes in a broad variety of malignancies. High levels of PD-L1 promote tumour growth by restraining CD8+ T-cell responses against tumors. Limiting PD-L1 expression and function is therefore critical for allowing the development of anti-tumour immune responses and effective tumour clearance. PKM2 is also a key player in regulating cancer as well as immune responses. PKM2 catalyzes the final rate-limiting step of glycolysis. Furthermore PKM2 as a dimer translocates to the nucleus, where it stimulates Hif-1α transactivation domain function and recruitment of p300 to the Hif-1α response elements (HRE) of Hif-1α target genes. Here, we provide the first evidence of a role for PKM2 in regulating the expression of PD-L1 on macrophages, dendritic cells (DCs), T cells and tumour cells. LPS-induced expression of PD-L1 in primary macrophages was inhibited by the PKM2 targeting compound TEPP-46. Furthermore, RNA silencing of PKM2 inhibited LPS-induced PD-L1 expression. This regulation occurs through direct binding of PKM2 and Hif-1α to HRE sites on the PD-L1 promoter. Moreover, TEPP-46 inhibited expression of PD-L1 on macrophages, DCs and T cells as well as tumour cells in a mouse CT26 cancer model. These findings broaden our understanding of how PKM2 may contribute to tumour progression, and may explain the upregulation of PD-L1 in the tumour microenvironment.